ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.37+1.17%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ICCC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 56.8% |
| Our one-year growth estimate | diamond | -33.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 90.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ICCC — litigation filed
Dated 2026-06-10
Regulation FD Disclosure In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equipment for expanded production of the Company’s flagship First Defense® product line. On June 4, 2026, ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program to execute on that strategy. The first phase, whic…
Why it matters: The first expansion phase aims to add reliable supply. On-time completion would support the planned rise in output.
Supportive ifThe company reports that the $3.5 million freeze-drying project is complete by June 30, 2027, and that the new dryer is working.
Worry ifThe company reports a delay past June 30, 2027, a cost above $3.5 million, or trouble getting the new dryer to work.
Why it matters: Q2 margin fell after low output and scrap from a material quality issue. Better results would show those pressures eased.
Supportive ifA later quarterly report shows gross margin above 33.9%. Scrap costs from the purchased material do not return.
Worry ifA later report shows gross margin at or below 33.9%, or cites repeat scrap costs or low output.
Why it matters: Q3 growth covered Tri-Shield, Dual-Force, and the new feed line. Continued gains would show growth reaches more than one product.
Supportive ifThe next full results show year-over-year sales growth for Tri-Shield and Dual-Force, with growth in the Functional Feed line.
Worry ifThe next full results show lower sales for Tri-Shield or Dual-Force year over year, or lower Functional Feed sales.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$116 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $487 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,773 loss on $10,000 · 27.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.